Regenerative Respiratory Tract Prostheses
A regenerative respiratory tract prosthesis comprising a tubular extracellular matrix (ECM) member having a lumen therethrough, at least first and second biodegradable polymeric anchors disposed on the tubular member exterior surface. The first and second anchors can include a microneedle tissue engagement member.
1 . A regenerative respiratory tract prosthesis, comprising:
a tubular member comprising an decellularized extracellular matrix (ECM) material, said tubular member having a interior and exterior surface, and proximal and distal ends, said interior surface defining a conduit through said member;
at least a first biodegradable anchor disposed on said tubular member exterior surface and proximate said tubular member proximal end; and
at least a second biodegradable anchor disposed on said tubular member exterior surface proximate said tubular member distal end,
said first and second anchors comprising a biodegradable polymeric material selected from the group consisting of polyhydroxyalkonates (PHAs), polylactides (PLLA) and polyglycolides (PLGA) and copolymers of said PLGA.
2 . The respiratory tract prosthesis of claim 1 , wherein said prosthesis further comprises at least a third biodegradable anchor disposed on said tubular member exterior surface between said first and second anchors.
3 . The respiratory tract prosthesis of claim 1 , wherein said first and second anchors comprise polymeric material selected from the group consisting of polyesters, poly(amino acids), polyanhydrides, polyorthoesters, polyurethanes, polycarbonates, homopolymers and copolymers of poly(lactic acid) and poly(glycolic acid), copolyesters of e-caprolactone, trimethylene carbonate, and para-dioxanone.
4 . The respiratory tract prosthesis of claim 1 , wherein said first and second anchors comprise artificial/semi-synthetic hyaline cartilage.
5 . The respiratory tract prosthesis of claim 1 , wherein said first and second anchors comprise a collagen matrix comprising chondroitin-6-sulfate.
6 . The respiratory tract prosthesis of claim 1 , wherein said first and second anchors comprise magnesium.
7 . The respiratory tract prosthesis of claim 1 , wherein said first and second anchors comprise cross-linked extracellular matrix (ECM).
8 . The respiratory tract prosthesis of claim 1 , wherein said ECM material comprises ECM selected from the group consisting of small intestine submucosa (SIS), urinary bladder submucosa (UBS), stomach submucosa (SS), dermal extracellular matrix, subcutaneous extracellular matrix, gastrointestinal extracellular matrix, placental extracellular matrix, omomentum extracellular matrix, cardiac extracellular matrix, kidney extracellular matrix, pancreas extracellular matrix, lung extracellular matrix, and combinations thereof.
9 . The respiratory tract prosthesis of claim 1 , wherein said ECM material comprises at least one supplemental biologically active agent.
10 . The respiratory tract prosthesis of claim 9 , wherein said supplemental biologically active agent comprises a HMG-CoA reductase inhibitor selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin.
11 . The respiratory tract prosthesis of claim 9 , wherein said supplemental biologically active agent comprises a cell selected from the group consisting of human embryonic stem cells, fetal cardiomyocytes, myofibroblasts, mesenchymal stem cells, autotransplated expanded cardiomyocytes, adipocytes, totipotent cells, pluripotent cells, blood stem cells, myoblasts, adult stem cells, bone marrow cells, mesenchymal cells, embryonic stem cells, parenchymal cells, epithelial cells, endothelial cells, mesothelial cells, fibroblasts, osteoblasts, chondrocytes, exogenous cells, endogenous cells, stem cells, hematopoietic stem cells, bone-marrow derived progenitor cells, myocardial cells, skeletal cells, fetal cells, undifferentiated cells, multi-potent progenitor cells, unipotent progenitor cells, monocytes, cardiac myoblasts, skeletal myoblasts, macrophages, capillary endothelial cells, xenogenic cells, allogenic cells, and post-natal stem cells.
12 . The respiratory tract prosthesis of claim 9 , wherein said supplemental biologically active agent comprises a growth factor selected from the group comprising a platelet derived growth factor (PDGF), epidermal growth factor (EGF), transforming growth factor-α (TGF-α), transforming growth factor beta (TGF-β), fibroblast growth factor-2 (FGF-2), basic fibroblast growth factor (bFGF), vascular epithelial growth factor (VEGF), hepatocyte growth factor (HGF), insulin-like growth factor (IGF), nerve growth factor (NGF), platelet derived growth factor (PDGF), tumor necrosis factor α (TNA-α), and placental growth factor (PLGF).
13 . The respiratory tract prosthesis of claim 1 , wherein said ECM material comprises at least one pharmacological agent.
14 . The respiratory tract prosthesis of claim 13 , wherein said pharmacological agent comprises an agent selected from the group consisting of antibiotics, anti-virals, anesthetics, analgesics and anti-inflammatories.
15 . A regenerative respiratory tract prosthesis, comprising:
a tubular member comprising an acellular extracellular matrix (ECM) material, said tubular member having a interior and exterior surface, and proximal and distal ends, said interior surface defining a conduit through said member;
at least a first biodegradable anchor disposed on said tubular member interior surface and proximate said tubular member proximal end; and
at least a second biodegradable anchor disposed on said tubular member interior surface proximate said ECM member distal end,
said first and second anchors comprising a biodegradable polymeric material selected from the group consisting of polyhydroxyalkonates (PHAs), polylactides (PLLA) and polyglycolides (PLGA) and copolymers of said PLGA.
16 . The respiratory tract prosthesis of claim 15 , wherein said prosthesis further comprises at least a third biodegradable anchor disposed on said tubular member interior surface between said first and second anchors.
17 . The respiratory tract prosthesis of claim 15 , wherein said first and second anchors comprise polymeric material selected from the group consisting of polyesters, poly(amino acids), polyanhydrides, polyorthoesters, polyurethanes, polycarbonates, homopolymers and copolymers of poly(lactic acid) and poly(glycolic acid), copolyesters of e-caprolactone, trimethylene carbonate, and para-dioxanone.
18 . The respiratory tract prosthesis of claim 15 , wherein said first and second anchors comprise artificial/semi-synthetic hyaline cartilage.
19 . The respiratory tract prosthesis of claim 15 , wherein said first and second anchors comprise a collagen matrix comprising chondroitin-6-sulfate.
20 . The respiratory tract prosthesis of claim 15 , wherein said first and second anchors comprise magnesium.
21 . The respiratory tract prosthesis of claim 15 , wherein said first and second anchors comprise cross-linked extracellular matrix (ECM).
22 . The respiratory tract prosthesis of claim 15 , wherein said ECM material comprises ECM selected from the group consisting of small intestine submucosa (SIS), urinary bladder submucosa (UBS), stomach submucosa (SS), dermal extracellular matrix, subcutaneous extracellular matrix, gastrointestinal extracellular matrix, placental extracellular matrix, ornomentum extracellular matrix, cardiac extracellular matrix, kidney extracellular matrix, pancreas extracellular matrix, lung extracellular matrix, and combinations thereof.
23 . The respiratory tract prosthesis of claim 15 , wherein said ECM material comprises at least one supplemental biologically active agent.
24 . The respiratory tract prosthesis of claim 23 , wherein said supplemental biologically active agent comprises a I-IMG-CoA reductase inhibitor selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin.
25 . The respiratory tract prosthesis of claim 23 , wherein said supplemental biologically active agent comprises a cell selected from the group consisting of human embryonic stem cells, fetal cardiomyocytes, myofibroblasts, mesenchymal stem cells, autotransplated expanded cardiomyocytes, adipocytes, totipotent cells, pluripotent cells, blood stem cells, myoblasts, adult stem cells, bone marrow cells, mesenchymal cells, embryonic stem cells, parenchymal cells, epithelial cells, endothelial cells, mesothelial cells, fibroblasts, osteoblasts, chondrocytes, exogenous cells, endogenous cells, stem cells, hematopoietic stem cells, bone-marrow derived progenitor cells, myocardial cells, skeletal cells, fetal cells, undifferentiated cells, multi-potent progenitor cells, unipotent progenitor cells, monocytes, cardiac myoblasts, skeletal myoblasts, macrophages, capillary endothelial cells, xenogenic cells, allogenic cells, and post-natal stem cells.
26 . The respiratory tract prosthesis of claim 23 , wherein said supplemental biologically active agent comprises a growth factor selected from the group comprising a platelet derived growth factor (PDGF), epidermal growth factor (EGF), transforming growth factor-α (TGF-α), transforming growth factor beta (TGF-β), fibroblast growth factor-2 (FGF-2), basic fibroblast growth factor (bFGF), vascular epithelial growth factor (VEGF), hepatocyte growth factor (HGF), insulin-like growth factor (IGF), nerve growth factor (NGF), platelet derived growth factor (PDGF), tumor necrosis factor α (TNA-α), and placental growth factor (PLGF).
27 . The respiratory tract prosthesis of claim 15 , wherein said ECM material comprises at least one pharmacological agent.
28 . The respiratory tract prosthesis of claim 27 , wherein said pharmacological agent comprises an agent selected from the group consisting of antibiotics, anti-virals, anesthetics, analgesics and anti-inflammatories.
29 . A regenerative respiratory tract prosthesis, comprising:
a tubular member comprising an extracellular matrix (ECM) composition, said ECM composition comprising acellular ECM from a mammalian tissue source,
said tubular member having an interior and exterior surface, and proximal and distal ends, said interior surface defining a conduit through said tubular member,
said tubular member being capable of transitioning from a first pre-deployment configuration, wherein said tubular member is capable of being positioned at a target position in a respiratory tract structure, to an expanded first post-deployment configuration, wherein said tubular member is capable of being disposed proximate host tissue of said a respiratory tract structure;
a first expandable anchor disposed in said conduit of said tubular member on said interior surface and proximate said proximal end; and
a second expandable anchor disposed in said conduit of said tubular member on said interior surface proximate said distal end,
said first expandable anchor and said second expandable anchor being capable of transitioning from a second pre-deployment configuration when said tubular member is in said first pre-deployment configuration, to a second post-deployment configuration, thereby causing said tubular member to assume said expanded first post-deployment configuration, and wherein said first expandable anchor and said second expandable anchor engage and support said tubular member at a first region proximate said interior surface, and wherein said first expandable anchor and said second expandable anchor are capable of positioning said exterior surface at said host tissue of said respiratory tract structure and maintain said positioning during a trigger phase, flow delivery phase, cycle phase and expiratory phase of a ventilator cycle for a temporary anchor support period of time,
said second post-deployment configuration of said first expandable anchor and said second expandable anchor comprising a circular planar shape,
said first expandable anchor and said second expandable anchor being configured to exert a diminishing supporting force on said tubular member in second post-deployment configuration that diminishes to 0 lb. after said temporary anchor support period of time.
30 . The respiratory tract prosthesis of claim 29 , wherein said temporary anchor support period of time is during a process of tissue regeneration.
33 . The respiratory tract prosthesis of claim 29 , wherein said first expandable anchor and said second expandable anchor comprise a biocompatible shape memory alloy.
34 . The respiratory tract prosthesis of claim 33 , wherein said biocompatible shape memory alloy comprises a nickel-titanium alloy.
35 . The respiratory tract prosthesis of claim 29 , wherein said first expandable anchor and said second expandable anchor each anchors comprise a respective single anchor ring.
37 . The respiratory tract prosthesis of claim 29 , wherein said mammalian tissue source is selected from the group consisting of small intestine submucosa (SIS), urinary bladder submucosa (UBS), stomach submucosa (SS), subcutaneous extracellular matrix, gastrointestinal extracellular matrix, placental extracellular matrix, omentum extracellular matrix, cardiac extracellular matrix, kidney extracellular matrix, pancreas extracellular matrix, lung extracellular matrix, mesothelial tissue and combinations thereof.
38 . The respiratory tract prosthesis of claim 37 , wherein said ECM composition comprises at least one supplemental biologically active agent.
39 . The respiratory tract prosthesis of claim 38 , wherein said supplemental biologically active agent comprises a HMG-CoA reductase inhibitor selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin.
40 . The respiratory tract prosthesis of claim 38 , wherein said supplemental biologically active agent comprises a cell selected from the group consisting of human embryonic stem cells, fetal cardiomyocytes, myofibroblasts, mesenchymal stem cells, autotransplated expanded cardiomyocytes, adipocytes, blood stem cells, myoblasts, adult stem cells, bone marrow cells, parenchymal cells, epithelial cells, endothelial cells, mesothelial cells, fibroblasts, osteoblasts, chondrocytes, bone-marrow derived progenitor cells, myocardial cells.
41 . The respiratory tract prosthesis of claim 38 , wherein said supplemental biologically active agent comprises a growth factor selected from the group comprising transforming growth factor-α (TGF-α), transforming growth factor beta (TGF-β), fibroblast growth factor-2 (FGF-2), vascular epithelial growth factor (VEGF), hepatocyte growth factor (HGF), insulin-like growth factor (IGF), and placental growth factor (PLGF).
42 . The respiratory tract prosthesis of claim 29 , wherein said ECM composition comprises at least one pharmacological agent selected from the group consisting of an antibiotic, anti-viral, anesthetic, analgesic and anti-inflammatory.